Alloplastic injectable dermal filler and methods of use thereof
View Patent ↗A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent comprising particles of the unsubstituted acrylate/substituted acrylate copolymer with a diameter of less than about 100μ. Methods for making a composition comprising an alloplastic injectable suspension for use as a dermal filler are provided. Methods of augmenting soft tissue to provide long-term reduction of a skin defect and the stimulation of collagen production are also provided.
1. A composition comprising:
an alloplastic injectible suspension comprising particles of an unsubstituted acrylate/substituted acrylate copolymer; wherein the particles of the unsubstituted acrylate/substituted acrylate copolymer have a diameter of less than about 100μ.
2. The composition of claim 1 , wherein the particles have a diameter of less than about 10μ.
3. The composition of claim 1 , wherein the particles have a diameter of about 0.01μ to about 10μ.
4. The composition of claim 1 , wherein the particles have a diameter of about 0.1μ to about 5μ.
5. The composition of claim 1 , wherein the substituted acrylate monomer of the unsubstituted acrylate/substituted acrylate copolymer is substituted with a methyl group.
6. The composition of claim 1 , wherein the substituted acrylate monomer is substituted with a hydrocarbon chain of two, three, four or five carbons.
7. The composition of claim 1 , wherein the substituted acrylate monomer is substituted with a halogen group.
8. The composition of claim 1 , wherein the substituted acrylate monomer is substituted with a nitrile group.
9. A composition comprising:
an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent;
wherein the biocompatible and pliable material is a copolymer of an unsubstituted acrylate monomer and a substituted acrylate monomer, wherein the biocompatible and pliable material comprises particles having a diameter of less than about 100μ.
10. The composition of claim 9 , wherein the particles have a diameter of less than about 10μ.
11. The composition of claim 9 , where in the particles have a diameter of about 0.01μ to about 10μ.
12. The composition of claim 9 , wherein the particles have a diameter of about 0.1μ to about 5μ.
13. The composition of claim 9 , wherein the acrylate/methacrylate copolymer is a finely ground solid.
14. The composition of claim 13 , wherein the finely ground solid is a powder.
15. The composition of claim 13 , wherein the finely ground solid is a non-porous microbead.
16. The composition of claim 13 , wherein the finely ground solid is a microsphere.
17. The composition of claim 13 , wherein the physiologically acceptable suspending agent is resorbable.
18. The composition of claim 9 , wherein the physiologically acceptable suspending agent is a buffered physiological solution.
19. The composition of claim 9 , wherein the physiologically acceptable suspending agent comprises cross-linked sodium hyaluronate.
20. The composition of claim 9 , wherein the physiologically acceptable suspending agent comprises a non cross-linked sodium hyaluronate.
21. The composition of claim 9 , wherein the physiologically acceptable suspending agent comprises collagen.
22. The composition of claim 21 , wherein the collagen is derived from an animal.
23. The composition of claim 21 , wherein the collagen is derived from a bird.
24. The composition of claim 21 , wherein the collagen is genetically engineered.
25. The composition of claim 9 , further comprising a local anesthetic.
26. A biocompatible medical device comprising the composition of claim 9 .
27. A method of making the composition of claim 9 comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent.
28. The method of claim 27 , wherein the acrylate/methacrylate copolymer is a solid.
29. The method of claim 28 , wherein the solid is a powder.
30. The method of claim 28 , wherein the solid is a non-porous microbead.
31. The method of claim 28 , wherein the solid is a microsphere.
32. The method of claim 28 , wherein the solid has a diameter of about 10μ to about 100μ.
33. The method of claim 28 , wherein the solid has a diameter of about 0.01μ to about 10μ.
34. A method of preparing the composition of claim 9 comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent;
wherein the biocompatible and pliable material is an acrylate/methacrylate copolymer, and wherein the acrylate/methacrylate copolymer is finely ground before admixing.
35. The method of claim 34 , wherein the acrylate/methacrylate copolymer is a finely ground solid.
36. The method of claim 34 , wherein the finely ground solid is a powder.
37. The method of claim 34 , wherein the finely ground solid is a non-porous microbead.
38. The method of claim 34 , wherein the finely ground solid is a microsphere.
39. The method of claim 34 , wherein the finely ground solid has a diameter of from about 0.01μ to about 10μ.
40. A method of augmenting soft tissue to provide long-term reduction of a skin defect comprising stimulating collagen production, fibroblast production, fibrocyte production or production of any combination thereof, beneath the skin defect, wherein the stimulation of collagen production fibroblast production, fibrocyte production or production of any combination thereof is effected by injecting into the deep reticular dermis the composition of claim 9 .
41. The method of claim 40 , comprising injecting the dermal filler below the skin defect at a junction of the dermis and subcutaneous fat.
42. The method of claim 40 , wherein the injected dermal filler produces little immunologic response in the host tissue or no immunologic response in the host tissue.
43. The method of claim 40 , wherein the skin defect is a result of loss of collagen and hyaluronic acid in the skin during the aging process.
44. The method of claim 40 , wherein the skin defect is a result of premature aging, said premature aging caused by overexposure to sunlight, overexposure to environmental pollutants, smoking tobacco products, exposure to cigarette smoke, poor nutrition and skin disorders.
45. The method of claim 40 , wherein the skin defect is a dynamic wrinkle, a fine wrinkles or a static wrinkle.
46. The method of claim 45 , wherein the dynamic wrinkle is a forehead crease, a brow burrow or an eye line (crow's feet).
47. The method of claim 45 , wherein the static wrinkle is a skin fold wrinkle resulting from sagging skin.
48. The method of claim 40 , wherein the skin defect is a medical condition selected from the group consisting of an acne scar, a surgical scar, a large pore and a soft tissue contour defect.
49. The method of claim 40 , wherein the long-term reduction of the skin defect is of a duration of at least one year.
50. The method of claim 40 , wherein the long-term reduction of the skin defect is of a duration of from at least one year to about five years.
51. The method of claim 40 , wherein the long-term reduction of the skin defect is of a duration from about five years to about ten years.
52. The method of claim 40 , wherein the long-term reduction of the skin defect is of a duration from about ten years or longer.
53. A method of administering a dermal filler to a subject comprising injecting into the deep reticular dermis of the subject the composition of claim 9 .
54. The method of claim 53 , wherein the finely ground solid has a diameter of from about 0.01μ to about 10μ.
55. The method of claim 53 , comprising injecting the dermal filler below a skin defect at a junction of the dermis and subcutaneous fat.
56. A method of treating a skin defect in a subject comprising: administering to the subject the composition of claim 9 .